 | • レポートコード：MRC2302E0158 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、233ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：産業装置 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に2,334.51百万ドルであった世界のキャリアスクリーニング市場規模が、2022年に2,676.57百万ドルになり、2027年まで年平均14.82%で成長して5,352.01百万ドルに達すると予測しています。本レポートでは、キャリアスクリーニングの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（拡張型キャリアスクリーニング、標的疾患キャリアスクリーニング）分析、病状別（血液疾患、神経疾患、呼吸器疾患）分析、技術別（DNAシーケンシング、マイクロアレイ、ポリメラーゼ連鎖反応）分析、エンドユーザー別（病院、医院＆クリニック、リファレンスラボラトリー）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、23Andme Inc.、Abbott Laboratories、Autogenomics Inc.、BGI、Centogene、Danaher Corporation、Eurofins Scientific、F. Hoffmann-La Roche AG、Fulgent Genetics Inc、Gene By Gene、Illumina Inc.、Invitae Corporation、Laboratory Corporation of America Holdings、Luminex Corporationなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のキャリアスクリーニング市場規模：種類別 - 拡張型キャリアスクリーニングの市場規模 - 標的疾患キャリアスクリーニングの市場規模 ・世界のキャリアスクリーニング市場規模：病状別 - 血液疾患スクリーニングの市場規模 - 神経疾患スクリーニングの市場規模 - 呼吸器疾患スクリーニングの市場規模 ・世界のキャリアスクリーニング市場規模：技術別 - DNAシーケンシング技術の市場規模 - マイクロアレイ技術の市場規模 - ポリメラーゼ連鎖反応技術の市場規模 ・世界のキャリアスクリーニング市場規模：エンドユーザー別 - 病院における市場規模 - 医院＆クリニックにおける市場規模 - リファレンスラボラトリーにおける市場規模 ・世界のキャリアスクリーニング市場規模：地域別 - 南北アメリカのキャリアスクリーニング市場規模 アメリカのキャリアスクリーニング市場規模 カナダのキャリアスクリーニング市場規模 ブラジルのキャリアスクリーニング市場規模 ... - アジア太平洋のキャリアスクリーニング市場規模 日本のキャリアスクリーニング市場規模 中国のキャリアスクリーニング市場規模 インドのキャリアスクリーニング市場規模 韓国のキャリアスクリーニング市場規模 台湾のキャリアスクリーニング市場規模 ... -ヨーロッパ/中東/アフリカのキャリアスクリーニング市場規模 イギリスのキャリアスクリーニング市場規模 ドイツのキャリアスクリーニング市場規模 フランスのキャリアスクリーニング市場規模 ロシアのキャリアスクリーニング市場規模 ... -その他地域のキャリアスクリーニング市場規模 ・競争状況 ・企業情報 |
The Global Carrier Screening Market size was estimated at USD 2,334.51 million in 2021 and expected to reach USD 2,676.57 million in 2022, and is projected to grow at a CAGR 14.82% to reach USD 5,352.01 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Carrier Screening to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Expanded Carrier Screening and Targeted Disease Carrier Screening. The Expanded Carrier Screening is further studied across Customized Panel Testing and Predesigned Panel Testing.
Based on Medical Condition, the market was studied across Hematological Conditions, Neurological Conditions, and Pulmonary Conditions.
Based on Technology, the market was studied across DNA Sequencing, Microarrays, and Polymerase Chain Reaction.
Based on End User, the market was studied across Hospitals, Physician Offices and Clinics, and Reference Laboratories.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Carrier Screening market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Carrier Screening Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Carrier Screening Market, including 23Andme Inc., Abbott Laboratories, Autogenomics Inc., BGI, Centogene, Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche AG, Fulgent Genetics Inc, Gene By Gene, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Medgenome, Myriad Genetics, Natera Inc, Opko Health, Otogenetics Corporation, Pathway Genomics, Progenity, Quest Diagnostics Incorporated, Sema4, Sequenom Inc., Thermo Fisher Scientific Inc, and True Health.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Carrier Screening Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Carrier Screening Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Carrier Screening Market?
4. What is the competitive strategic window for opportunities in the Global Carrier Screening Market?
5. What are the technology trends and regulatory frameworks in the Global Carrier Screening Market?
6. What is the market share of the leading vendors in the Global Carrier Screening Market?
7. What modes and strategic moves are considered suitable for entering the Global Carrier Screening Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Focus on early disease detection and prevention
5.1.1.2. Advancing maternal ages and high risk of chromosomal abnormalities
5.1.1.3. Increased awareness and prevalence of recessive genetic disorders globally
5.1.2. Restraints
5.1.2.1. Dearth of skilled professionals and professional services
5.1.3. Opportunities
5.1.3.1. Improved POC diagnostics
5.1.3.2. Technical advancement in carrier screening
5.1.4. Challenges
5.1.4.1. Loosely defined standards and guidelines
5.2. Cumulative Impact of COVID-19
6. Carrier Screening Market, by Type
6.1. Introduction
6.2. Expanded Carrier Screening
6.3.1. Customized Panel Testing
6.3.2. Predesigned Panel Testing
6.3. Targeted Disease Carrier Screening
7. Carrier Screening Market, by Medical Condition
7.1. Introduction
7.2. Hematological Conditions
7.3. Neurological Conditions
7.4. Pulmonary Conditions
8. Carrier Screening Market, by Technology
8.1. Introduction
8.2. DNA Sequencing
8.3. Microarrays
8.4. Polymerase Chain Reaction
9. Carrier Screening Market, by End User
9.1. Introduction
9.2. Hospitals
9.3. Physician Offices and Clinics
9.4. Reference Laboratories
10. Americas Carrier Screening Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Carrier Screening Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Carrier Screening Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 23Andme Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbott Laboratories
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Autogenomics Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. BGI
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Centogene
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Danaher Corporation
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Eurofins Scientific
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. F. Hoffmann-La Roche AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Fulgent Genetics Inc
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Gene By Gene
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Illumina Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Invitae Corporation
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Laboratory Corporation of America Holdings
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Luminex Corporation
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Medgenome
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Myriad Genetics
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Natera Inc
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Opko Health
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Otogenetics Corporation
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Pathway Genomics
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Progenity
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Quest Diagnostics Incorporated
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Sema4
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Sequenom Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Thermo Fisher Scientific Inc
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. True Health
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing